Disparities in neoadjuvant chemotherapy for pancreatic adenocarcinoma with vascular involvement.

Nikhil Chervu, Shineui Kim, Sara Sakowitz, Nguyen Le, Saad Mallick, Hanjoo Lee, Peyman Benharash, Timothy Donahue

Abstract read

In one paragraph

Article in Surgery open science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nikhil ChervuDepartment of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

Shineui KimDepartment of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

Sara SakowitzDepartment of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

Nguyen LeDepartment of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

Saad MallickDepartment of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

Hanjoo LeeDepartment of Surgery, Harbor-UCLA Medical Center, Torrance, CA, USA.

Peyman BenharashDepartment of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

Timothy DonahueDivision of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, UCLA, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Multiagent neoadjuvant chemotherapy (NAT) has been linked with improved survival for locally advanced (LA) or borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC). However, the existence of disparities in its utilization remains to be elucidated. Methods: All adults with PDAC were tabulated from the 2011-2017 Nationwide Cancer Database. Tumor vascular involvement was determined using the clinical T stage and CS_EXTENSION variables. The significance of temporal trends was calculated using Cuzick's non-parametric test. A Cox proportional hazard model was used to assess the impact of NAT utilization on hazard of two-year mortality. A logistic regression model was developed to determine factors associated with receipt of NAT. Results: Of 3811 patients meeting inclusion criteria, 50.8 % received NAT. NAT utilization significantly increased over the study period, from 31.7 % in 2011 to 81.1 % in 2017 ( Conclusions: We identified increasing utilization of NAT for BR/LA pancreatic adenocarcinoma. Despite being linked with significantly reduced two-year mortality, socioeconomic disparities affect odds of NAT.

Indexed as

Borderline resectableDisparitiesLocally advancedNeoadjuvant therapyPancreatic adenocarcinomaPancreatic cancer

Identifiers

PMID39021616

DOI10.1016/j.sopen.2024.06.003

PMCPMC11252929

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.